Bizengri (bispecific antibody) Acquired by Partner Therapeutics | Healthcare M&A Deal

Partner Therapeutics has completed the acquisition of Bizengri (bispecific antibody), a pharmacy business in the United States, for an undisclosed amount. Bizengri is a bispecific antibody designed to treat advanced cholangiocarcinoma driven by NRG1 gene fusions, supporting targeted oncology care. Partner Therapeutics acquisitions in healthcare M&A focus on expanding its oncology pipeline through strategic acquisition of specialized biologics. The divestiture acquisition was announced after Partner Therapeutics acquired U.S. rights from Merus in 2024, reflecting a strategic acquisition by a strategic buyer to strengthen commercial access to an FDA-approved therapy.